High Specificity of Quantitative Methylation-Specific PCR Analysis for MGMT Promoter Hypermethylation Detection in Gliomas

Table 2

MGMT promoter methylation status in primary tumour and recurrences by quantitative methylation-specific PCR (QMSP) and Methylation-Specific PCR (MSP).

Patient	Hystological* type	Months^§	Sample^#	QMSP^¶		QMSP^¶	MSP^¶
				Median	IQR
G3	GB	0	FFPE	28.41	13.28–47.82	pos	pos
	GB	28	FFPE	12.8	11.07–16.00	pos	pos
	GB	29	FFPE	209.37	101.70–226.68	pos	pos
G8	GB	0	FFPE	0	0-0	neg	neg
	GB	10	FFPE	0	0-0	neg	neg
G24	GB	0	FFPE	0	0-0	neg	neg
	GB	9	SF	5.98	4.37–7.60	pos	pos

*GB: Glioblastoma. ^§number of months from first surgery. ^#FFPE: Formalin fixed paraffin-embedded sample; SF: Snap-frozen pecimen. ^¶IQR: Interquartile range; pos: Methylation levels for QMSP exceed the cutoff point of 0.35, a band is seen in gel electrophoresis for MSP; neg: Methylation levels for QMSP are below the cutoff point of 0.35, no band is seen in gel electrophoresis for MSP.